Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung Cancer.

JCO precision oncology·2026

Same author

Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461].

The journal of liquid biopsy·2026

Same author

Who Gets Left Out of Precision Oncology? Real-World Driver Mutation Expression Patterns and Therapeutic Eligibility in a Diverse Single-Center Early-Stage Lung Adenocarcinoma Cohort.

Journal of racial and ethnic health disparities·2026

Same author

Evaluation of zongertinib for the treatment of metastatic non-squamous non-small cell lung cancer with <i>HER2</i> TKD activating mutation.

Expert opinion on pharmacotherapy·2026

Same author

Deep learning of CT imaging predicts PD-L1 expression and immunotherapy response in metastatic NSCLC: A multi-center study.

Cancer letters·2026

Same author

Immune Checkpoint Inhibitors in Unresectable or Metastatic Thymic Epithelial Tumors--A Real-World Assessment of Efficacy and Toxicity.

Clinical lung cancer·2026

Search research articles

Related Experiment Video

Updated: Feb 20, 2026

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

Circulating DNA in EGFR-mutated lung cancer.

Aditi P Singh¹, Shenduo Li², Haiying Cheng¹

¹Department of Oncology, Montefiore Medical Center, Bronx, NY, USA.

Annals of Translational Medicine

|October 24, 2017

Summary

Circulating tumor DNA (ctDNA) offers a less invasive method for detecting epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). This blood-based test complements tissue biopsies for improved diagnosis and monitoring.

Keywords:

Circulating tumor DNA (ctDNA)epidermal growth factor receptor mutation (EGFR mutation)liquid biopsy non-small cell lung cancer (NSCLC)

More Related Videos

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Experiment Videos

Last Updated: Feb 20, 2026

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

Non-small cell lung cancer (NSCLC) treatment has advanced with targeted therapies for EGFR mutations.
Tissue biopsy is the standard for EGFR mutation assessment but has limitations.
Circulating tumor DNA (ctDNA) presents a promising alternative for molecular profiling.

Purpose of the Study:

To review the role of ctDNA in EGFR-mutated NSCLC.
To highlight ctDNA's applications in diagnosis and treatment monitoring.
To discuss ctDNA's utility in detecting resistance mechanisms.

Main Methods:

Review of studies on ctDNA analysis in NSCLC.
Focus on digital PCR and next-generation sequencing for EGFR mutation detection.
Evaluation of ctDNA's sensitivity and specificity compared to tissue biopsy.

Main Results:

ctDNA analysis is a reliable complement to traditional tumor genotyping.
Plasma-based ctDNA detection of EGFR mutations is highly sensitive and specific.
ctDNA aids in overcoming limitations of tissue biopsies.

Conclusions:

ctDNA is valuable for EGFR mutation detection in NSCLC patients.
Emerging applications include diagnosis, surveillance, and treatment monitoring.
ctDNA facilitates the detection of acquired resistance mechanisms to targeted therapies.